An increase in depressive symptoms after myocardial infarction predicts new cardiac events irrespective of depressive symptoms before myocardial infarction

M. Zuidersma[1]*, J. Ormel[1], H. J. Conradi[1,2] and P. de Jonge[1]

[1] *Interdisciplinary Center for Psychiatric Epidemiology, Department of Psychiatry, University Medical Center Groningen, University of Groningen, The Netherlands*
[2] *Department of Clinical Psychology, University of Amsterdam, The Netherlands*

Background. Depression after myocardial infarction (MI) is associated with poor cardiovascular prognosis. There is some evidence that specifically depressive episodes that develop after the acute event are associated with poor cardiovascular prognosis. The aim of the present study was to evaluate whether an increase in the number of depressive symptoms after MI is associated with new cardiac events.

Method. In 442 depressed and 325 non-depressed MI patients the Composite International Diagnostic Interview interview to assess post-MI depression was extended to evaluate the presence of the ICD-10 depressive symptoms just before and after the MI. The effect of an increase in number of depressive symptoms during the year following MI on new cardiac events up to 2.5 years post-MI was assessed with Cox regression analyses.

Results. Each additional increase of one symptom was significantly associated with a 15% increased risk of new cardiac events, and this was stronger for non-depressed than for depressed patients. This association was independent of baseline cardiac disease severity. There was no interaction with the number of depressive symptoms pre-MI.

Conclusions. Our findings suggest that an increase in depressive symptoms after MI irrespective of the state of depression pre-MI explains why post-MI depression is associated with poor cardiovascular prognosis. Also increases in depressive symptoms after MI resulting in subthreshold depression should be evaluated as a prognostic marker. Whether potential mechanisms such as cardiac disease severity or inflammation underlie the association remains to be clarified.

Introduction

In myocardial infarction (MI) patients, the prevalence of depressive disorder is about 20% (Thombs *et al.* 2006), compared with 2% in the general population of comparable age (Beekman *et al.* 1999). Moreover, de-pressed MI patients have a twofold increased risk of poor cardiac prognosis, including all-cause mortality, cardiovascular mortality and new cardiovascular events than those who are not depressed (Meijer *et al.* 2011).

Recent studies suggest that this risk of poor prognosis differs among subgroups of depressed cardiac patients. At particularly increased risk are those with

* Address for correspondence : M. Zuidersma, M.Sc., Interdisciplinary Center for Psychiatric Epidemiology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, PO Box 30001, 9700 RB Groningen, The Netherlands.

(Email : m.zuidersma@med.umcg.nl)

persistent or treatment-resistant depression (Carney *et al.* 2004; Kaptein *et al.* 2006; de Jonge *et al.* 2007; Glassman *et al.* 2009), somatic depressive symptoms (de Jonge *et al.* 2006*a*; Linke *et al.* 2009; Martens *et al.* 2010), anhedonia (Davidson *et al.* 2010) and first-ever depressive episodes (Grace *et al.* 2005; Carney *et al.* 2009).

There is some evidence that depressed MI patients are at particular increased risk of poor prognosis when the depressive episode has an onset after rather than before the acute event (de Jonge *et al.* 2006*b*; Dickens *et al.* 2008; Parker *et al.* 2008), but results are incon-sistent (Glassman *et al.* 2009; Zuidersma *et al.* 2011). Moreover, MI patients with depressive episodes with an onset after the MI were found to have had a more severe MI than those with depressive episodes with an onset before the MI (Spijkerman *et al.* 2005).

The finding that the onset of the depressive episode relative to the MI is associated with new

cardiovascular events helps in identifying those depressed MI patients with the highest risk. Furthermore, it suggests that the prognostic impact of post-MI depression has an aetiology related to the MI itself. Depression after MI results from either a prolongation of a pre-existing depression or an increase in depressive symptoms after the event, or both. The finding that depressive episodes with an onset after the MI are associated with new cardiovascular events suggests that it is the increase in depressive symptoms after the MI that explains the poor prognosis associated with depression. Therefore, an increase in depressive symptoms after MI could also be associated with poor prognosis if it does not lead to a full diagnosis of depression, or if it occurs on top of a pre-existing depressive episode. No study has yet evaluated whether cardiac prognosis is associated with an increase in depressive symptoms after MI as a continuous measure. In the present study we evaluate whether an increase in depressive symptoms after MI is associated with poor prognosis in the presence and absence of post-MI depression.

Method

Description of the studies and participants

The present analysis included depressed and non-depressed MI patients enrolled in two studies: (1) the Depression after Myocardial Infarction study (DepreMI) – a prognostic study evaluating the effects of depression on cardiovascular prognosis in MI patients; and (2) the Myocardial Infarction and Depression Intervention Trial (MIND-IT) – a randomized controlled trial evaluating the effects of antidepressant treatment in depressed MI patients. Both studies were highly similar in patient recruitment, eligibility criteria, assessment of depression and participation rates.

DepreMI

DepreMI was a prognostic study evaluating the effects of depression on cardiovascular prognosis in MI patients receiving usual cardiac aftercare. Details of this study have been described previously (Spijkerman *et al.* 2006). Patients admitted for MI were recruited from four hospitals in the north of the Netherlands between September 1997 and September 2000. To be included, patients had to have chest pain for at least 20 min, increased enzyme levels, and new pathological Q-waves on the electrocardiogram in at least two leads. Excluded were patients with a life expectancy of less than a year due to non-cardiac conditions, poor physical function, cognitive dysfunction, who were unable to speak or read Dutch, and when follow-up visits were scheduled in a non-participating

hospital. The study protocol was approved by the ethics committee review board of each of the four participating hospitals.

MIND-IT

MIND-IT was a multicentre randomized controlled trial evaluating the effects of antidepressant treatment in depressed MI patients (for details, see van den Brink *et al.* 2002; van Melle *et al.* 2007). Briefly, patients admitted for MI to one of 11 hospitals in the Netherlands were recruited consecutively between September 1999 and November 2002. To be included, patients had to be ≥18 years of age, and had to have a documented increase in cardiac enzymes together with chest pain during at least 20 min or typical electrocardiographic changes. Exclusion criteria were the presence of a disease likely to influence short-time survival, being unable to participate (e.g. not able to communicate or not available for follow-up), already receiving psychiatric care for depression, and participating in another clinical trial. The intervention included prescription of antidepressant medication and/or referral to psychotherapy. The institutional review board at each clinical centre approved the protocol. The treatment was not effective in improving long-term depression status (i.e. 18 months post-MI) nor in reducing the risk of new cardiac events (van Melle *et al.* 2007).

Assessment of demographic and clinical parameters

Demographic and clinical characteristics were assessed during hospital admission for the index MI and from hospital charts. The presence of diabetes mellitus was assessed from the medical charts during hospital stay for the index MI. Smoking was defined as current smoker or quit smoking less than 3 months before hospital admission. Left ventricular ejection fraction (LVEF) was assessed by echocardiography, radionuclide ventriculography, gated single photon emission computed tomography, magnetic resonance imaging, angiography or clinical assessment. In MIND-IT, a modified version (Watkins *et al.* 2003) of the Charlson Comorbidity Index (Charlson *et al.* 1987) was calculated as a composite measure of somatic comorbidities.

Assessment of a diagnosis of depression

In DepreMI, at 3 and 12 months after the MI, the presence of a post-MI depressive episode according to International Classification of Diseases, 10th revision (ICD-10) criteria (World Health Organization, 1993) was assessed with the Composite International Diagnostic Interview version 1.1 (CIDI; World Health

Organization, 1990). In MIND-IT, patients were screened for depressive symptoms with the Beck Depression Inventory (BDI) (Beck *et al.* 1979) in the hospital and at 3 months after the MI. Those scoring 10 or higher were administered the CIDI, version 2.1 at 3 months after the MI to assess whether ICD-10 criteria for a post-MI depressive episode were met. Those with a score below 10 on the BDI and those who did not meet ICD-10 criteria for a post-MI depressive episode were assessed for depression again 3 months later. Assessments for depression were made up to 12 months after the MI.

Change in depressive symptoms after MI

In both studies, the change in depressive symptoms after MI was obtained from the first CIDI interview where the diagnosis of depression was made (i.e. 3, 6, 9 or 12 months after the MI for depressed patients and 3 months after the MI for non-depressed patients). For this goal, the CIDI was extended with additional questions to assess the presence of each ICD-10 symptom of depression during the 4 weeks before MI and after the MI. Symptoms were graded as either present or absent. A change score was calculated by subtracting the number of depressive symptoms present during the 4 weeks before the MI from the number of depressive symptoms present after the MI. In MIND-IT, the presence of depressive symptoms just before and after the MI was not assessed in non-depressed patients. Therefore, non-depressed patients were included from DepreMI only.

New cardiac events

New fatal and non-fatal cardiac events occurring after the depression interview were included as endpoints and were assessed by patient interviews, hospital records and data from treating specialists. Endpoints included cardiac deaths and hospital readmissions for recurrent MI, unstable angina, heart failure and arrhythmia. An independent endpoint committee consisting of at least two cardiologists evaluated whether potential endpoints were cardiac related. The follow-up period started at the date of the interview where the diagnosis for depression was established (i.e. 3, 6, 9 or 12 months post-MI for depressed patients and 3 months post-MI for non-depressed patients) and lasted up to 18 months (MIND-IT) or 2.5 years after the index MI (DepreMI).

Statistics

First, demographic and clinical characteristics at the time of the MI were compared between included and excluded study participants with the χ^2 or the independent-sample Student's *t* test. This was repeated for the patients with and without data on new cardiac events.

Next, for the included patients, demographic and clinical characteristics were associated with the continuous measure of the change in number of depressive symptoms after MI with the Mann–Whitney *U* test and Spearman correlation.

Cox regression was used to assess whether time to first new cardiac event was associated with an increase in depressive symptoms after MI. A hazard ratio (HR) was calculated for new cardiac events associated with each symptom increase. Adjustments for covariables were made stepwise: model 1 adjusted for age and sex, model 2 additionally for LVEF and previous MI because these relate to both depression and cardiac prognosis (van Melle *et al.* 2005; Naqvi *et al.* 2007), model 3 additionally for diabetes and smoking because these relate to depression as well as cardiac disease (Critchley & Capewell, 2003; Dawood *et al.* 2008; Mezuk *et al.* 2008), and model 4 additionally adjusted for those cardiac parameters that were associated with an increase in the number of depressive symptoms after MI to explore the possibility that other cardiac disease severity parameters explain the association between an increase in number of depressive symptoms after MI and new cardiac events.

To evaluate whether the presence of somatic comorbidities could explain the association between an increase in depressive symptoms and cardiac events, adjustments were made for the Charlson Comorbidity Index. This was done for MIND-IT patients only, because the Charlson Comorbidity Index was only assessed in MIND-IT. To evaluate whether the occurrence of new cardiac events before depression assessment confounded the association between an increase in depressive symptoms after MI and new cardiac events: (1) adjustment was made for new cardiac events before the interview; and (2) patients with a cardiac event before depression assessment were excluded. This was done for DepreMI only, because in MIND-IT new cardiac events occurring before the depression assessment were not assessed.

Next, the presence of a dose–response relationship between an increase in depressive symptoms and cardiac events was evaluated. First, it was evaluated whether the risk of having a new cardiac event linearly increases with larger increases in depressive symptoms. For this purpose, the HR for new cardiac events associated with an increase of (1) one or two, (2) three or four, or (3) more than four symptoms increase was calculated, using a decrease or no change in number of symptoms as a reference. Second, it was evaluated whether an increase in depressive symptoms is linearly associated with the number of new cardiac

events by calculating a Spearman correlation between the increase in number of depressive symptoms and the total number of cardiac events per follow-up year.

Next, to evaluate whether the association between an increase in number of depressive symptoms after MI and new cardiac events differs between patients with few and many symptoms just before the MI, an interaction term was calculated of the number of depressive symptoms pre-MI and the increase in number of depressive symptoms after MI. With Cox regression the HR for new cardiac events was calculated for the interaction term with the two main terms in the same model, and in a next step additionally with all covariables included in model 4. A multicollinearity test was done for the number of depressive symptoms pre-MI, the increase in depressive symptoms after MI and the interaction term.

As a sensitivity analysis, the survival analyses were repeated for: (1) depressed and non-depressed patients separately to evaluate whether results differ for patients with and without an ICD-10 diagnosis of post-MI depression; and (2) only patients who had a CIDI at 3 months post-MI to evaluate whether results differ due to the timing of assessment of change in depression symptoms after MI. The significance level for all analyses was set at $p < 0.05$ (two-tailed).

Results

Sample

A flow chart for patients of DepreMI and MIND-IT is shown in Fig. 1. Of the 2705 participants (2177 from MIND-IT and 528 from DepreMI), 835 (31%) patients had complete data on the change in number of depressive symptoms after MI. Of these 835 patients, new cardiac events were evaluated in 767 (92%) patients, of whom 442 met ICD-10 criteria for a post-MI depressive episode. Of these 767 patients, 163 (21.3%) had a new cardiac event during a mean follow-up time of 1.43 (S.D. = 0.86) years.

Characteristics of included and excluded patients

Compared with the 1938 excluded patients, the 767 who were included in the present analysis were younger, more likely to be smokers, to have lower LVEF, higher Killip class, to have thrombolysis during hospitalization for the index MI, more likely to be prescribed a calcium channel blocker, less likely to have hypercholesterolaemia and less likely to be prescribed statins and beta-blockers. Included and excluded participants did not differ on sex, body mass index (BMI), smoking, anterior site MI, revascularization during hospitalization for index MI, history of

MI, family history of coronary artery disease (CAD), diabetes, hypertension, peripheral vascular disease, cerebrovascular disease, and the Charlson Comorbidity Index (assessed in MIND-IT only).

Compared with the 767 included patients, the 68 with no data on new cardiac events more often had percutaneous transluminal coronary angioplasty (PTCA) and less often thrombolysis during hospitalization for index MI. They did not differ on any of the other investigated clinical variables (see above).

Prevalence of depressive symptoms before and after MI

Table 1 shows for each of the ten ICD-10 symptoms of depression the number of patients and percentages with the symptom before and after the MI. This is done separately for the 442 patients with post-MI depression and the 325 non-depressed patients. It shows that the largest proportion of depressive symptoms after the MI is attributable to new development. However, there seems to be no difference in new development between individual symptoms. In addition, the proportion of patients reporting a symptom to be present before MI but absent after MI was very small, ranging between 0.8% (appetite problems) and 5.5% (fatigue).

Change in number of depressive symptoms after MI and baseline characteristics

Table 2 compares demographic and clinical characteristics for 272 patients with a decrease or no change in depressive symptoms after MI and 495 patients with an increase in depressive symptoms after MI. An increase in the number of depressive symptoms was associated with younger age, smoking, low LVEF, anterior site MI, PTCA during admission for the index MI, a family history of CAD, hypercholesterolaemia, and with first-ever depression.

Change in number of depressive symptoms after MI and new cardiac events

Fig. 2 shows the mean [95% confidence interval (CI)] number of depressive symptoms during the 4 weeks before MI and after the MI for patients who suffered a new cardiac event and those who remained event-free. Table 3 shows the results of the survival analysis. An increase of one depressive symptom was significantly associated with a 15% increased risk of new cardiac events. Adjustment for age, sex, LVEF, previous MI, presence of diabetes and smoking did not affect this association. Neither did adjustment for the cardiac parameters that were significantly associated with an increase in depressive symptoms after MI (anterior

Fig. 1. Flow-chart for patients of the Depression after Myocardial Infarction (DepreMI) study and Myocardial Infarction and Depression Intervention Trial (MIND-IT). CIDI, Composite International Diagnostic Interview; MI, myocardial infarction.
[a] These patients were not randomized and therefore not followed for new cardiac events.

site MI, PTCA during hospitalization for index MI, family history of CAD, hypercholesterolaemia). Adjustment for the Charlson Comorbidity Index in MIND-IT patients did not affect the HR. Adjustment for new cardiac events before the depression assessment affected the HR only slightly (from 1.09 to 1.07), as did exclusion of the 45 patients with a new cardiac event before depression assessment (HR 1.08).

There was a dose–response relationship between an increase in depressive symptoms and cardiac events, with unadjusted HRs of 1.70 (95% CI 1.09–2.66, $p=0.020$), 2.11 (95% CI 1.32–3.35, $p=0.002$) and 2.88 (95% CI 1.89–4.38, $p<0.001$) for an increase in one or two, three or four, and more than four symptoms,

respectively. In addition, the increase in number of depressive symptoms was positively correlated with the number of new cardiac events per follow-up year ($\rho=0.153$, $p<0.001$; see also Fig. 3).

The interaction term of the number of depressive symptoms pre-MI and the change in number of depressive symptoms after MI did not reach statistical significance. There was no multicollinearity between the number of symptoms pre-MI, the increase in depressive symptoms after MI and the interaction term (variance inflating factor varied between 1.16 and 1.42). The number of symptoms during the 4 weeks before MI was not associated with new cardiac events. The number of symptoms after the MI was

Table 1. *Prevalence of each ICD-10 depressive symptom during the 4 weeks before MI and after the MI, assessed in 767 MI patients*

	Patients with diagnosis of post-MI depression ($n=442$)			Patients with no post-MI depression ($n=325$)		
	Present before MI	Present after MI	Newly developed	Present before MI	Present after MI	Newly developed
Sadness	102 (23.1)	328 (74.2)	240 (73.2)	9 (2.8)	12 (3.7)	9 (75.0)
Loss of interest	81 (18.3)	278 (62.9)	214 (77.0)	12 (3.7)	19 (5.8)	13 (68.4)
Worthless/guilty	44 (10.0)	176 (39.8)	143 (81.2)	6 (1.8)	13 (4.0)	8 (61.5)
Low self-esteem	45 (10.2)	177 (40.0)	145 (81.9)	7 (2.2)	9 (2.8)	2 (22.2)
Concentration problems	93 (21.0)	314 (71.0)	236 (75.2)	23 (7.1)	62 (19.1)	50 (80.6)
Thoughts of death/suicide	40 (9.0)	166 (37.6)	133 (80.1)	8 (2.5)	19 (5.8)	14 (73.7)
Fatigue	141 (31.9)	363 (82.1)	236 (65.0)	49 (15.1)	60 (18.5)	39 (65.0)
Appetite problems	6 (1.4)	48 (10.9)	46 (95.8)	3 (0.9)	9 (2.8)	8 (88.9)
Sleeping problems	135 (30.5)	329 (74.4)	207 (62.9)	60 (18.5)	107 (32.9)	60 (56.1)
Psychomotor changes	76 (17.2)	238 (53.8)	180 (75.6)	24 (7.4)	42 (12.9)	27 (64.3)

ICD, International Classification of Diseases, 10th revision; MI, myocardial infarction.

Data are given as n (%).

Table 2. *Change in the number of depressive symptoms after MI and demographic and clinical characteristics in 767 MI patients*

	Decrease or no change in depressive symptoms after MI ($n=272$)	Increase in depressive symptoms after MI ($n=495$)	Z (Mann–Whitney U test)	Correlation coefficient (r)
Mean age, years (S.D.)	60.7 (11.2)	59.1 (11.5)		−0.101**
Male, n (%)	219 (80.5)	376 (76.0)	−1.476	
Mean BMI, kg/m² (S.D.)	26.9 (4.2)	26.6 (4.1)		−0.033
Smoking, n (%)	116 (45.8)	266 (56.4)	−2.322*	
Cardiac parameters				
Low LVEF[a], n (%)	71 (26.7)	159 (33.8)	−2.499*	
Anterior site of MI, n (%)	75 (27.6)	179 (36.2)	−2.360*	
Killip class ⩾2, n (%)	40 (14.7)	69 (14.0)	−0.375	
PTCA during hospitalization, n (%)	74 (27.7)	185 (38.6)	−4.901***	
CABG during hospitalization, n (%)	15 (5.6)	14 (2.9)	−1.523	
Thrombolysis during hospitalization, n (%)	119 (44.2)	207 (42.0)	−1.114	
History of MI, n (%)	44 (16.2)	69 (14.0)	−1.005	
Family history of CAD, n (%)	103 (38.0)	226 (46.0)	−3.460**	
Co-morbidity				
Diabetes, n (%)	25 (9.2)	61 (12.3)	−0.603	
Hypertension, n (%)	87 (32.0)	151 (30.5)	−0.050	
Hypercholesterolaemia, n (%)	113 (41.5)	312 (63.2)	−6.848***	
Peripheral vascular disease, n (%)	18 (6.6)	47 (9.5)	−1.059	
Cerebrovascular disease, n (%)	12 (4.4)	25 (5.1)	−0.419	
First-ever depression[b], n (%)	41 (65.1)	305 (80.5)	−2.831**	

MI, Myocardial infarction; S.D., standard deviation; BMI, body mass index; LVEF, left ventricular ejection fraction; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; CAD, coronary artery disease.

[a] Depression after Myocardial Infarction study (DepreMI): ⩽40%, Myocardial Infarction and Depression Intervention Trial (MIND-IT): ⩽45%.

[b] In 442 patients with post-MI depression ($n=92$, <2 symptoms increase; $n=350$, ⩾2 symptoms increase).

* $p<0.05$, ** $p<0.01$, *** $p<0.001$.

Fig. 2. Number of symptoms of depression during the 4 weeks before and after the myocardial infarction (MI) in patients with (□, *n* = 163) and without (■, *n* = 604) a new cardiac event. Values are means, with 95% confidence intervals represented by vertical bars.

significantly associated with new cardiac events, where each additional symptom accounted for a 15% increased risk.

The first sensitivity analysis showed that in the 442 MI patients with a post-MI depressive episode the association of an increase in the number of depressive symptoms after MI and new cardiac events was much weaker than in 325 non-depressed MI patients (see Table 3).

The second sensitivity analysis showed that after exclusion of 134 patients with a CIDI interview at 6, 9 or 12 months, the associations as shown in Table 3 were essentially the same (data not described here, but can be requested from M.Z.).

Discussion

In the present analysis we evaluated whether an increase in the number of depressive symptoms after MI rather than the prolongation of a pre-existing depressive episode explains why post-MI depression is associated with poor cardiac prognosis. We found a dose–response relationship between an increase in the number of depressive symptoms after MI and risk of new cardiac events. An increase of one single ICD-10 symptom (of which there are 10) was associated with a 15% increased risk. Although an increase in the number of depressive symptoms after MI was associated with cardiac disease severity at baseline, adjustment for cardiac disease severity did not affect the association with new cardiac events. Furthermore, there was no interaction with the number of depressive symptoms pre-MI. This result suggests that it is the increase

in depressive symptoms rather than the state of depression pre-MI that explains why post-MI depression is associated with new cardiac events.

Our study has a number of strengths. This is to our knowledge the first time that the impact of an increase in depression severity from just before to after an acute cardiac event on cardiac prognosis has been evaluated. We used a large sample of MI patients with and without post-MI depression and assessed the number of depressive symptoms just before and after the MI in a face-to-face interview. The sample was large enough to adjust for factors potentially confounding the association between the increase in depressive symptoms and new cardiac events. To evaluate to what extent our findings can be generalized to the whole MI population, patients included in the present analysis were compared with excluded participants on baseline demographic and medical characteristics. The oversampling of MI patients with a diagnosis of depression probably explains why the included patients had a slightly worse cardiac profile than those who were excluded. Apart from this, included patients were not much different from excluded patients. We therefore conclude that the associations we found are very likely to be representative for at least all study participants. In addition, there were no major differences in baseline characteristics between patients with and without data on new cardiac events.

A study that is somewhat comparable with ours is that of Dickens *et al.* (2008). In their study, 440 MI patients completed the Hospital Anxiety and Depression Scale (HADS) at two time points: (1) during hospitalization, but assessing depressive symptoms during the week preceding MI; and (2) at 12 months after the MI. They found that patients with new-onset depression (i.e. HADS score <17 preceding MI and ⩾17 at 12 months post-MI) were at increased risk of cardiac mortality up to 8 years post-MI compared with patients with pre-MI-onset depression (HADS score ⩾17 preceding MI) and non-depressed patients (HADS score <17 at both time points). Despite the difference in assessing the increase in depressive symptoms after MI (i.e. as a continuous measure with a diagnostic interview *versus* a cut-off score on a questionnaire), our finding is consistent with that of Dickens *et al.* (2008).

It may be that MI patients with depressive episodes with an onset after the MI are at increased risk of new cardiac events (de Jonge *et al.* 2006*b*; Dickens *et al.* 2008), because these patients show a larger increase in depressive symptoms after MI. That the increased risk associated with an increase in depressive symptoms after MI is comparable for patients with few and many symptoms of depression pre-MI suggests that an increase in depression after MI is also associated with

Table 3. *Risk of new cardiac events associated with the number of depressive symptoms just before and after MI and with an increase in number of depressive symptoms after MI*

Predictor	All patients (n=767)		Post-MI depression (n=442)		No post-MI depression (n=325)	
	HR (95% CI)[a]	p	HR (95% CI)[a]	p	HR (95% CI)[a]	p
Increase in number of symptoms						
Unadjusted	1.15 (1.09–1.21)	<0.001	1.08 (1.01–1.16)	0.022	1.21 (1.00–1.46)	0.046
Model 1[b]	1.15 (1.09–1.22)	<0.001	1.08 (1.01–1.16)	0.021	1.24 (1.02–1.52)	0.032
Model 2[c]	1.14 (1.08–1.20)	<0.001	1.07 (1.00–1.14)	0.054	1.27 (1.03–1.55)	0.024
Model 3[d]	1.13 (1.07–1.20)	<0.001	1.08 (1.00–1.15)	0.037	1.27 (1.02–1.58)	0.037
Model 4[e]	1.12 (1.06–1.19)	<0.001	1.08 (1.00–1.16)	0.038	1.20 (0.95–1.53)	0.132
Interaction between the number of depressive symptoms pre-MI and increase in number of symptoms after MI[f]	1.00 (0.97–1.03)	0.887	1.01 (0.97–1.04)	0.692	1.14 (0.96–1.36)	0.134
Interaction between the number of depressive symptoms pre-MI and increase in number of symptoms after MI[g]	1.01 (0.98–1.04)	0.719	1.01 (0.98–1.05)	0.546	1.04 (0.89–1.22)	0.613
Number of symptoms pre-MI (unadjusted)	1.00 (0.92–1.08)	0.963	0.91 (0.82–1.00)	0.049	1.12 (0.92–1.35)	0.259
Number of symptoms post-MI (unadjusted)	1.15 (1.09–1.22)	<0.001	1.06 (0.97–1.17)	0.224	1.26 (1.08–1.47)	0.003

MI, Myocardial infarction; HR, hazard ratio; CI, confidence interval; LVEF, left ventricular ejection fraction; PTCA, percutaneous transluminal coronary angioplasty; CAD, coronary artery disease.

[a] HRs indicate the increased risk associated with each additional symptom.

[b] Model 1 adjusted for age and sex.

[c] Model 2 adjusted for age, sex, LVEF and previous MI.

[d] Model 3 adjusted for age, sex, LVEF, previous MI, diabetes and smoking.

[e] Model 4 adjusted for age, sex, LVEF, previous MI, diabetes, smoking, anterior site MI, PTCA during hospitalization, family history of CAD and hypercholesterolaemia.

[f] This model included the number of depressive symptoms pre-MI, the increase in number of depressive symptoms after MI, and the interaction-term of these two.

[g] This model included the number of depressive symptoms pre-MI, the increase in number of depressive symptoms after MI, the interaction-term of these two and all variables in model 4.

Fig. 3. Number of new cardiac events per follow-up year with hazard ratios (HRs) and 95% confidence intervals for new cardiac events associated with different levels of increase in the number of depressive symptoms just after myocardial infarction. Values are means, with 95% confidence intervals represented by vertical bars.

poor prognosis: (1) in patients with depressive episodes with an onset before the MI; and (2) when it does not lead to a full diagnosis of depression after MI.

The association between the increase in depressive symptoms after MI and new cardiac events suggests that the increase in depressive symptoms as well as the increased risk of new cardiac events have an aetiology that is related to the MI, either due to the psychological meaning or the physiological consequences of the event. We found that an increase in depressive symptoms after MI was associated with some cardiac disease severity parameters. This suggests that cardiac disease severity plays a role in the increase in depressive symptoms after MI. However, the association between the increase in depressive symptoms after MI and new cardiac events was independent of cardiac disease severity, suggesting that cardiac disease severity *per se* does not explain the association. Still, we would not exclude cardiac disease severity as a potential underlying factor. Even though an association is independent of parameters that measure a certain underlying risk factor, the underlying risk factor may still underlie the association, because the parameters are inaccurately measured or there may be other influential unmeasured parameters (Davey Smith & Phillips, 1992; Macleod & Davey Smith, 2003; Christenfeld *et al.* 2004). For example, like in most prognostic studies on depression and cardiac disease, we measured cardiac disease severity parameters only during hospitalization and made no follow-up assessments. Therefore, we could not evaluate whether an increase in cardiac disease severity explained the poor prognosis in patients with an increase in depressive symptoms after MI. In addition, unmeasured parameters, such as severity of

atherosclerosis, could explain the poor prognosis of some patients. Another potential underlying risk factor may be inflammation. Higher levels of inflammatory markers are associated with established cardiac risk factors (such as systolic blood pressure, low-density lipoprotein cholesterol and BMI), and an increased risk of cardiovascular morbidity and mortality (Kaptoge *et al.* 2010), as well as with depression and increased depressive symptoms (Howren *et al.* 2009). An increase in depressive symptoms after MI may therefore be associated with an increase in inflammation, which in turn may explain the increased risk of new cardiac events. Whether or not an increase in depressive symptoms after MI is associated with inflammation is yet to be investigated. Still, instead of an underlying physiological process resulting in the increase in depressive symptoms after MI as well as the increased risk of new cardiac events, the increase in depressive symptoms after MI itself may be a precursor of behavioural changes that result in an increased risk of new cardiac events.

The association between an increase in depressive symptoms after MI and new cardiac events was weaker in depressed than in non-depressed MI patients. A possible explanation for this difference is that in depressed MI patients other risk factors, such as medication non-adherence, may overrule the effect of an increase in depressive symptoms after MI. Nevertheless, our finding shows that also in patients who do not meet criteria for post-MI depression, those at increased risk of new cardiac events can be identified. Therefore, also in MI patients with subthreshold levels of depression, it would be useful to assess changes in depression after MI as a prognostic marker for new cardiac events.

Of the patients with post-MI depression, a larger increase in the number of depressive symptoms after MI was associated with first-ever depression. There is some evidence that first-ever depression in MI patients is associated with poor cardiovascular outcomes (Grace *et al.* 2005; Carney *et al.* 2009), but results are inconsistent (Glassman *et al.* 2009; Zuidersma *et al.* 2011). In the present analysis, first-ever depression was not significantly associated with an increased risk of new cardiac events (HR for new cardiac events: 1.17, 95% CI 0.73–1.89). Although the results from the present analysis suggest an overlap between first-ever depression and an increase in depressive symptoms after MI, first-ever depression does not seem to explain the increased risk of poor prognosis in patients with an increase in depressive symptoms after MI.

Some considerations should be taken into account when interpreting the findings of the present analysis. One is the retrospective assessment of depressive symptoms just before MI, which may have been

subject to recall bias. The presence of previous depressive episodes in the lifetime is often underestimated, especially by subjects with better current mood (Kendler *et al.* 2001; Wells & Horwood, 2004; Patten, 2009). In addition, recall of depression just before MI may have been influenced by the MI itself. Therefore, recall bias may have affected the results of the present study. However, for most participants in the present study the recall period was no more than 4 months and Kendler *et al.* (2001) found recall to be significantly better with shorter recall periods. Therefore, in the present analysis, underestimation of depression just before MI as well as the effect of current depression severity on this underestimation may well be less prominent. In addition, exclusion of patients who had their depression assessed more than 3 months after the MI did not affect the results, giving a reason to believe that recall bias did not affect the results. Another consideration is that receiving psychiatric treatment at the moment of the index MI was an exclusion criterion in MIND-IT. This may have led to the exclusion of patients who were more depressed just before the MI, which could have influenced the results. For DepreMI, a scheduled follow-up visit in a non-participating hospital was an exclusion criterion, which led to the exclusion of 44 patients. This could have introduced some selection bias.

In summary, findings from the present study suggest that an increase in depressive symptoms after MI rather than prolongation of a pre-MI depressive episode explains why post-MI depression is associated with new cardiac events. The increased risk of new cardiac events associated with an increase in depressive symptoms after MI was higher in patients not meeting diagnostic criteria for post-MI depression than in those with post-MI depression. Therefore, also in patients with subthreshold levels of depression, an increase in depressive symptoms after MI should be assessed as a prognostic marker. Studies should be done to investigate whether potential mechanisms such as cardiac disease severity and inflammation underlie the association.

Acknowledgements

Declaration of Interest

None.

References

Beck AT, Rush AJ, Shaw BF, Emery G (1979). *Cognitive Therapy of Depression*. Guilford: New York.

Beekman AT, Copeland JR, Prince MJ (1999). Review of community prevalence of depression in later life. *British Journal of Psychiatry* **174**, 307–311.

Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab PG, Kaufmann PG, Czajkowski SM, Jaffe AS (2004). Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. *Psychosomatic Medicine* **66**, 466–474.

Carney RM, Freedland KE, Steinmeyer B, Blumenthal JA, de Jonge P, Davidson KW, Czajkowski SM, Jaffe AS (2009). History of depression and survival after acute myocardial infarction. *Psychosomatic Medicine* **71**, 253–259.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of Chronic Diseases* **40**, 373–383.

Christenfeld NJ, Sloan RP, Carroll D, Greenland S (2004). Risk factors, confounding, and the illusion of statistical control. *Psychosomatic Medicine* **66**, 868–875.

Critchley JA, Capewell S (2003). Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: a systematic review. *JAMA: The Journal of the American Medical Association* **290**, 86–97.

Davey Smith G, Phillips AN (1992). Confounding in epidemiological studies: why 'independent' effects may not be all they seem. *BMJ* **305**, 757–759.

Davidson KW, Burg MM, Kronish IM, Shimbo D, Dettenborn L, Mehran R, Vorchheimer D, Clemow L, Schwartz JE, Lesperance F, Rieckmann N (2010). Association of anhedonia with recurrent major adverse cardiac events and mortality 1 year after acute coronary syndrome. *Archives of General Psychiatry* **67**, 480–488.

Dawood N, Vaccarino V, Reid KJ, Spertus JA, Hamid N, Parashar S (2008). Predictors of smoking cessation after a myocardial infarction: the role of institutional smoking cessation programs in improving success. *Archives of Internal Medicine* **168**, 1961–1967.

de Jonge P, Honig A, van Melle JP, Schene AH, Kuyper AM, Tulner D, Schins A, Ormel J (2007). Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events. *American Journal of Psychiatry* **164**, 1371–1378.

de Jonge P, Ormel J, van den Brink RH, van Melle JP, Spijkerman TA, Kuijper A, van Veldhuisen DJ, van den Berg MP, Honig A, Crijns HJ, Schene AH

(2006*a*). Symptom dimensions of depression following myocardial infarction and their relationship with somatic health status and cardiovascular prognosis. *American Journal of Psychiatry* **163**, 138–144.

de Jonge P, van den Brink RH, Spijkerman TA, Ormel J (2006*b*). Only incident depressive episodes after myocardial infarction are associated with new cardiovascular events. *Journal of the American College of Cardiology* **48**, 2204–2208.

Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, Creed F (2008). New onset depression following myocardial infarction predicts cardiac mortality. *Psychosomatic Medicine* **70**, 450–455.

Glassman AH, Bigger Jr JT, Gaffney M (2009). Psychiatric characteristics associated with long-term mortality among 361 patients having an acute coronary syndrome and major depression: seven-year follow-up of SADHART participants. *Archives of General Psychiatry* **66**, 1022–1029.

Grace SL, Abbey SE, Kapral MK, Fang J, Nolan RP, Stewart DE (2005). Effect of depression on five-year mortality after an acute coronary syndrome. *American Journal of Cardiology* **96**, 1179–1185.

Howren MB, Lamkin DM, Suls J (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosomatic Medicine* **71**, 171–186.

Kaptein KI, de Jonge P, van den Brink RH, Korf J (2006). Course of depressive symptoms after myocardial infarction and cardiac prognosis: a latent class analysis. *Psychosomatic Medicine* **68**, 662–668.

Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. *Lancet* **375**, 132–140.

Kendler KS, Gardner CO, Prescott CA (2001). Are there sex differences in the reliability of a lifetime history of major depression and its predictors? *Psychological Medicine* **31**, 617–625.

Linke SE, Rutledge T, Johnson BD, Vaccarino V, Bittner V, Cornell CE, Eteiba W, Sheps DS, Krantz DS, Parashar S, Bairey Merz CN (2009). Depressive symptom dimensions and cardiovascular prognosis among women with suspected myocardial ischemia: a report from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. *Archives of General Psychiatry* **66**, 499–507.

Macleod J, Davey Smith G (2003). Depression as risk factor for mortality after coronary artery bypass surgery. *Lancet* **362**, 1500–1501.

Martens EJ, Hoen PW, Mittelhaeuser M, de Jonge P, Denollet J (2010). Symptom dimensions of post-myocardial infarction depression, disease severity and cardiac prognosis. *Psychological Medicine* **40**, 807–814.

Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P (2011). Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. *General Hospital Psychiatry* **33**, 203–216.

Mezuk B, Eaton WW, Albrecht S, Golden SH (2008). Depression and type 2 diabetes over the lifespan: a meta-analysis. *Diabetes Care* **31**, 2383–2390.

Naqvi TZ, Rafique AM, Andreas V, Rahban M, Mirocha J, Naqvi SS (2007). Predictors of depressive symptoms post-acute coronary syndrome. *Gender Medicine* **4**, 339–351.

Parker GB, Hilton TM, Walsh WF, Owen CA, Heruc GA, Olley A, Brotchie H, Hadzi-Pavlovic D (2008). Timing is everything: the onset of depression and acute coronary syndrome outcome. *Biological Psychiatry* **64**, 660–666.

Patten SB (2009). Accumulation of major depressive episodes over time in a prospective study indicates that retrospectively assessed lifetime prevalence estimates are too low. *BMC Psychiatry* **9**, 19.

Spijkerman T, de Jonge P, van den Brink RH, Jansen JH, May JF, Crijns HJ, Ormel J (2005). Depression following myocardial infarction: first-ever *versus* ongoing and recurrent episodes. *General Hospital Psychiatry* **27**, 411–417.

Spijkerman TA, van den Brink RH, May JF, Winter JB, van Melle JP, de Jonge P, Crijns HJ, Ormel J (2006). Decreased impact of post-myocardial infarction depression on cardiac prognosis? *Journal of Psychosomatic Research* **61**, 493–499.

Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, Fauerbach JA, Bush DE, Ziegelstein RC (2006). Prevalence of depression in survivors of acute myocardial infarction. *Journal of General Internal Medicine* **21**, 30–38.

van den Brink RH, van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, Ormel J (2002). Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). *American Heart Journal* **144**, 219–225.

van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, Schins A, Tulner D, van den Berg MP, Ormel J (2007). Effects of antidepressant treatment following myocardial infarction. *British Journal of Psychiatry* **190**, 460–466.

van Melle JP, de Jonge P, Ormel J, Crijns HJ, van Veldhuisen DJ, Honig A, Schene AH, van den Berg MP (2005). Relationship between left ventricular dysfunction and depression following myocardial infarction: data from the MIND-IT. *European Heart Journal* **26**, 2650–2656.

Watkins LL, Schneiderman N, Blumenthal JA, Sheps DS, Catellier D, Taylor CB, Freedland KE (2003). Cognitive and somatic symptoms of depression are associated with medical comorbidity in patients after acute myocardial infarction. *American Heart Journal* **146**, 48–54.

Wells JE, Horwood LJ (2004). How accurate is recall of key symptoms of depression? A comparison of recall and longitudinal reports. *Psychological Medicine* **34**, 1001–1011.

World Health Organization (1990). *Composite International Diagnostic Interview* (*CIDI*). WHO: Geneva.

World Health Organization (1993). *The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research*. WHO: Geneva.

Zuidersma M, Thombs BD, de Jonge P (2011). Onset and recurrence of depression as predictors of cardiovascular prognosis in depressed ACS-patients: a systematic review. *Psychotherapy and Psychosomatics* **80**, 227–237.